Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. The news could pressure Gilead stock.

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Gilead Sciences has shared positive top-line results from a late-stage study evaluating its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) with Merck & Co’s anti-PD-1 therapy ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy (sacituzumab govitecan-hziy) and MSD’s Keytruda (pembrolizumab ...

Gilead Sciences announced significant results from a Phase 3 study of Trodelvy combined with Merck's Keytruda in treating ...

April 21 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's (MRK.N), opens new tab immunotherapy ...